Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yanira Perez-Vera"'
Autor:
Carlos Sánchez-Piedra, Diana Sueiro-Delgado, Javier García-González, Inmaculada Ros-Vilamajo, Agueda Prior-Español, Manuel José Moreno-Ramos, Blanca Garcia-Magallon, Jerusalen Calvo-Gutiérrez, Yanira Perez-Vera, Raquel Martín-Domenech, Dolores Ruiz-Montesino, Paloma Vela-Casasempere, Lorena Expósito, Fernando Sánchez-Alonso, Enrique González-Davila, Federico Díaz-González
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim
Externí odkaz:
https://doaj.org/article/c21d7032e4634106a34eddf55c0f0d5e
Autor:
Federico Díaz-González, Manuel José Moreno-Ramos, Yanira Perez-Vera, Diana Sueiro-Delgado, Águeda Prior-Español, Enrique González-Dávila, Fernando Sánchez-Alonso, Raquel Martín-Domenech, Paloma Vela-Casasempere, Jerusalen Calvo-Gutiérrez, Blanca Garcia-Magallon, Dolores Ruiz-Montesino, Lorena Expósito, Javier García-González, Carlos Sánchez-Piedra, Inmaculada Ros-Vilamajo
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196dad6c26b86d18af8469b9012ea8fa
https://doi.org/10.1038/s41598-021-94504-x
https://doi.org/10.1038/s41598-021-94504-x
Autor:
Federico Díaz-González, María Colazo, Carlos Sánchez-Piedra, Juan J. Gomez-Reino, Yanira Perez-Vera, Fernando Sánchez-Alonso, Ana P. Ortiz, M. Rojas-Giménez, Sagrario Bustabad, Mercedes González, Paloma Vela-Casasempere, Águeda Prior-Español, Dolores Ruiz-Montesinos
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background During the last 15 years, the comprehensive understanding of the safety, effectiveness, expanding access, and availability of new biologic disease-modifying antirheumatic drugs (bDMARDs) has likely contributed to the pattern of use of thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3da290ee5441aceabd95e5a0cdf0fb2
https://doi.org/10.1136/annrheumdis-2019-eular.3181
https://doi.org/10.1136/annrheumdis-2019-eular.3181